< Back to all clusters
[HEALTH] · Italy, Belgium · 19 sources

started · updated

Medical advancements and biotech policy updates in Europe

Medical experts have highlighted the efficacy of depemokimab, a monoclonal antibody targeting interleukin 5 (IL-5), for treating severe eosinophilic asthma and nasal polyposis. Presented at the European Respiratory Society congress, Cristiano Caruso of Fondazione Policlinico Gemelli noted that the drug provides rapid clinical benefits and maintains effectiveness for up to two years. A distinctive feature of depemokimab is its administration schedule, which requires only one dose every six months.

In a separate development regarding the European biotech sector, stakeholders met in Brussels to discuss the upcoming Biotech Act. The meeting addressed the need for increased competitiveness and faster patient access to innovative therapies, as one in ten Europeans lives with an autoimmune disease. Discussions emphasized the growing investment gap between Europe and the United States, noting that the US R&D investment lead has expanded significantly over recent decades.

Entities

Brussels · Cristiano Caruso · European Parliament · European Respiratory Society · European Union · Fabrizio Celia · Fondazione Policlinico Gemelli · argenx

Claims

What the coverage asserts, and how many sources carry each claim.

Sources

12 days ago